Adial Pharmaceuticals, Inc. (ADIL)

Over the past six months, Adial Pharmaceuticals' stock price has significantly declined. In February 2026, a 1-for-25 reverse stock split was announced to regain Nasdaq compliance, and the company applauded a Congressional directive advancing alternative clinical trial endpoints for substance use disorders. In January 2026, an international PCT patent application for AD04 was published. In November 2025, the company reported its Third Quarter 2025 financial results and announced a warrant inducement transaction. In October 2025, Adial partnered with Genomind for a precision medicine testing solution. In September 2025, the company provided a business update following favorable comments from an FDA End-of-Phase 2 meeting for AD04 and received a Nasdaq extension to regain compliance with the minimum bid price rule.

Adial Pharmaceuticals' products and services do not typically exhibit traditional consumer demand seasonality. The demand for AD04 is primarily driven by the progress of its clinical trials, regulatory approvals, and eventual adoption by healthcare providers, which are not subject to seasonal fluctuations.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing prescription medications for addiction and related disorders. Their primary product candidate is AD04, a genetically targeted serotonin-3 receptor antagonist in Phase 3 clinical trials for Alcohol Use Disorder (AUD). The company also explores AD04's potential for other addictive disorders and develops drug candidates for non-opioid pain reduction, utilizing a proprietary companion diagnostic genetic test to identify suitable patients for AD04.

Adial Pharmaceuticals conducts its clinical research primarily in North America and has extended trials to select international sites. The company is based in Glen Allen, Virginia.

Adial Pharmaceuticals' brand reputation has been shaped by its clinical development progress and regulatory interactions. Milestones such as the publication of a patent application for AD04 and positive feedback from the FDA regarding the Phase 3 trial design have contributed positively. The company's public communications focus on advancing its lead drug candidate and strengthening its market position through strategic and regulatory efforts. There have been no explicitly negative events impacting its reputation beyond the stock performance.

Adial Pharmaceuticals, Inc. has a mix of institutional and individual owners. Institutional investors hold 2.53% of the stock, insiders own 19.25%, and retail investors hold 78.21%. Major institutional owners include Geode Capital Management, LLC, Vanguard Group Inc, and Citadel Advisors LLC. Key individual insider owners include Cary J. Claiborne, William B. Stilley III, and Bankole A. Johnson.